

Hemovigilance Module Adverse Reaction Transfusion Associated Graft vs. Host Disease

*Required for saving *Facility ID#: NHSN Adverse Reaction #: Patient Information *Patient ID: _____ *Gender: M F Other *Date of Birth: ___/__/ Social Security #: _____ Secondary ID: _____ Medicare #: _____ First Name: Middle Name: Last Name: Hispanic or Latino ☐ Not Hispanic or Not Latino Ethnicity American Indian/Alaska Native Asian Black or African American Race Native Hawaiian/Other Pacific Islander ☐ White ***Blood Group:** □ A- □ A+ □ B- □ B+ □ AB-□ AB+ □ 0-□0+ ☐ Blood type not done ☐ Transitional ABO / Rh + ☐ Transitional ABO / Rh -Transitional ABO / Transitional Rh ☐ Group A/Transitional Rh ☐ Group B/Transitional Rh ☐ Group O/Transitional Rh Group AB/Transitional Rh **Patient Medical History** List the patient's admitting diagnosis. (Use ICD-10 Diagnostic codes/descriptions) Code: Description: Description: Code: _____ Code: Description: List the patient's underlying indication for transfusion. (Use ICD-10 Diagnostic codes/descriptions) Code: _____ Description: Code: _____ Description: Code: Description: List the patient's comorbid conditions at the time of the transfusion related to the adverse reaction. (Use ICD-10 Diagnostic codes/descriptions) ☐ NONE Code: Description: Description: Code: _____ Code: Description: Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)). Public reporting burden of this collection of information is estimated to average 20 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS D-74, Atlanta, GA 30333 ATTN: PRA (0920-0666).



performed during the curre	ent hospital or outpatient stay. (Use ICD-10 Procedure
codes/descriptions) Code:	—
Code:	
Code:	
Transfusion History	
Has the patient received a	previous transfusion?
Blood Product:] WB ☐ RBC ☐ Platelet ☐ Plasma ☐ Cryoprecipitate ☐ Granulocyte
Date of Transfusion:	//
Was the patient's advers	se reaction transfusion-related?
If yes, provide information	n about the transfusion adverse reaction.
	erse reaction:
_	☐ PTP ☐ TACO ☐ TAD ☐ TA-GVHD ☐ TRALI ☐ UNKNOWN
	ify
Reaction Details	
	_// *Time reaction occurred:: :
-	ient was transfused:
Is this reaction associated wit	th an incident? Yes No If Yes, Incident #:
Investigation Results	
Investigation Results	d graft vs. host disease (TA-GVHD)
Investigation Results	
Investigation Results * Transfusion associated *Case Definition	
Investigation Results * Transfusion associated *Case Definition Did patient receive non-in	d graft vs. host disease (TA-GVHD)
Investigation Results * Transfusion associated *Case Definition Did patient receive non-in	d graft vs. host disease (TA-GVHD) radiated blood product(s) in the two months preceding the reaction?
Investigation Results * Transfusion associated *Case Definition Did patient receive non-in Check all that occurred to Clinical syndrome	d graft vs. host disease (TA-GVHD) radiated blood product(s) in the two months preceding the reaction?
Investigation Results * Transfusion associated *Case Definition Did patient receive non-in Check all that occurred to Clinical syndrome Clinical syndrome	d graft vs. host disease (TA-GVHD) radiated blood product(s) in the two months preceding the reaction? Yes No within 2 days to 6 weeks after cessation of transfusion:
Investigation Results * Transfusion associated *Case Definition Did patient receive non-in Check all that occurred to Clinical syndrome Clinical syndrome Liver dysfund Characteristic	d graft vs. host disease (TA-GVHD) radiated blood product(s) in the two months preceding the reaction?
Investigation Results * Transfusion associated *Case Definition Did patient receive non-in Check all that occurred to Clinical syndrome Clinical syndrome Liver dysfund Characteristic	d graft vs. host disease (TA-GVHD) radiated blood product(s) in the two months preceding the reaction?
Investigation Results * Transfusion associated *Case Definition Did patient receive non-in Check all that occurred to Clinical syndrome Clinical syndrome Liver dysfund Characteristic	d graft vs. host disease (TA-GVHD) radiated blood product(s) in the two months preceding the reaction?
Investigation Results * Transfusion associated *Case Definition Did patient receive non-in Check all that occurred to Clinical syndrome Clinical syndrome Clinical syndrome Liver dysfund Characteristic may, in severe of Check all that apply:	d graft vs. host disease (TA-GVHD) radiated blood product(s) in the two months preceding the reaction?
Investigation Results * Transfusion associated *Case Definition Did patient receive non-in Check all that occurred to Clinical syndrome Clinical syndrome Clinical syndrome Liver dysfund Characteristic may, in severe of Check all that apply:	d graft vs. host disease (TA-GVHD) radiated blood product(s) in the two months preceding the reaction? Yes No within 2 days to 6 weeks after cessation of transfusion: le characteristics: Diarrhea Fever Hepatomegaly Pancytopenia etion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) Marrow aplasia c rash: erythematous, maculopapular eruption centrally that spreads to extremities and cases, progress to generalized erythroderma and hemorrhagic bullous formation.
Investigation Results * Transfusion associated *Case Definition Did patient receive non-in Check all that occurred to Clinical syndrome Clinical syndrome Clinical syndrome Liver dysfund Characteristic may, in severe of Check all that apply: Characteristic history	d graft vs. host disease (TA-GVHD) radiated blood product(s) in the two months preceding the reaction? Yes No within 2 days to 6 weeks after cessation of transfusion: e characteristics: Diarrhea Fever Hepatomegaly Pancytopenia ction (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) Marrow aplasia crash: erythematous, maculopapular eruption centrally that spreads to extremities and cases, progress to generalized erythroderma and hemorrhagic bullous formation.
Investigation Results * Transfusion associated *Case Definition Did patient receive non-in Check all that occurred to Clinical syndrome Clinical syndrome Liver dysfund Characteristic may, in severe of Check all that apply: Characteristic histo Biopsy negative or	d graft vs. host disease (TA-GVHD) radiated blood product(s) in the two months preceding the reaction? Yes No within 2 days to 6 weeks after cessation of transfusion: e characteristics: Diarrhea Fever Hepatomegaly Pancytopenia ction (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) Marrow aplasia crash: erythematous, maculopapular eruption centrally that spreads to extremities and cases, progress to generalized erythroderma and hemorrhagic bullous formation.
Investigation Results * Transfusion associated *Case Definition Did patient receive non-in Check all that occurred to clinical syndrome Clinical syndrome Clinical syndrome Liver dysfund Characteristic may, in severe of check all that apply: Check all that apply: Characteristic histo Biopsy negative or content of the signs and symptoms	d graft vs. host disease (TA-GVHD) radiated blood product(s) in the two months preceding the reaction? Yes No within 2 days to 6 weeks after cessation of transfusion: le characteristics: Diarrhea Fever Hepatomegaly Pancytopenia ction (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) Marrow aplasia c rash: erythematous, maculopapular eruption centrally that spreads to extremities and cases, progress to generalized erythroderma and hemorrhagic bullous formation. logical appearance of skin or liver biopsy. not done. s: (check all that apply)
Investigation Results * Transfusion associated *Case Definition Did patient receive non-in Check all that occurred to clinical syndrome Clinical syndrome Clinical syndrome Clinical syndrome Characteristic may, in severe of check all that apply: Check all that apply: Characteristic histor Biopsy negative or Other signs and symptoms Generalized:	d graft vs. host disease (TA-GVHD) radiated blood product(s) in the two months preceding the reaction?



	Hemolysis/Hemorrhage:	 □ Disseminated intravascular coagulation □ Positive antibody screen 									
•	Pain:	☐ Abdominal pain ☐ Back pain ☐ Flank pain ☐ Infusion site pain									
	Renal:	☐ Hematuria ☐ Hemoglobinuria ☐ Oliguria									
•	Respiratory:	☐ Bronchospasm ☐ Cough ☐ Shortness of breath									
	Other: (specify)										
	*Severity										
	Did the patient receive or experience any of the following?										
	☐ No treatment required ☐ Symptomatic treatment only										
	☐ Hospitalization, inlouding prolonged hospitalization ☐ Life-threatening reaction										
	☐ Disability and/or in	capacitation Congenital anomaly or birth defect(s) of the fetus									
	Other medically im	portant conditions									
	*Imputability										
	Which best describes the relationship between the transfusion and the reaction?										
	☐ No other alternative diagnoses.										
	Other potential cau	ses are present (e.g., stem cell transplantation).									
	Alternative explanations are more likely (e.g., solid organ transplantation).										
	Evidence is clearly	n favor of a cause other than the transfusion, but transfusion cannot be excluded.									
	☐ There is conclusive	evidence beyond reasonable doubt of a cause other than the transfusion									
	☐ The relationship between the adverse reaction and the transfusion is unknown or not stated.										
	Did the transfusion occur	at your facility?									
	WBC chimerism:	WBC chimerism present									
Mc	odule-generated Desig	nations									
	_	definition, severity, and imputability will be automatically assigned in the NHSN es in the corresponding investigation results section above.									
	*Do you agree with the	case definition designation? ☐ YES ☐ NO									
	^Please indicate your de	signation									
	*Do you agree with the										
	^Please indicate your de	signation									
		imputability designation? ☐ YES ☐ NO									
Pa	*Please indicate your de	SIGNATION									
	^Please indicate your de atient Treatment	signation									
	atient Treatment										
ı	atient Treatment	tment for the transfusion reaction?									
I	Did the patient receive trea	tment for the transfusion reaction?									
I	Did the patient receive trea	tment for the transfusion reaction?	<u> </u>								
ı	Did the patient receive treat If yes, select treatment(s) Medication (Select Antipyretics	tment for the transfusion reaction?	.								
ı	Did the patient receive treat If yes, select treatment(s) Medication (Select Antipyretics	tment for the transfusion reaction?	;								



 ☐ Respiratory support (Select the type of support) ☐ Mechanical ventilation ☐ Noninvasive ventilation ☐ Oxygen 															
☐ Renal replacement therapy (Select the type of therapy)☐ Hemodialysis ☐ Peritoneal ☐ Continuous Veno-Venous Hemofiltration															
☐ Phlebotomy ☐ Other Specify:															
Outcome															
*Outcome: Death Major or long-term sequelae Minor or no sequelae Not determined															
Date of Death:/															
^ If 1	^If recipient died, relationship of transfusion to death:														
	☐ Definite ☐ Probable ☐ Possible ☐ Doubtful ☐ Ruled Out ☐ Not determined														
	of death:						_								
vvas an	autopsy performed?	Yes	☐ No												
Component		1 : (:		- () (-l										
*Was a partic	cular unit implicated	d in (i.e., respo	onsibl	e for) the a	dverse	☐ Yes	s 🗌	No [] N/A						
Transfusion Start and End Date/Time	*Component code (check system used)	Amount transfused at reaction onset	(Requ	number ired for on and	*Unit expiration Date/Time	*Blood group		Implicat ed Unit?							
^IMPLICATED						1									
/ /	☐ ISBT-128														
		☐ Entire unit				□ A-	□ A+	☐ B-							
	Codahar				/ /				Υ						
:	☐ Codabar	Partial unit			/			□ AB.	-						
	Codabar					□B+	□ АВ-	□ AB+							
:		Partial unit			::			□ AB+							
: // :		Partial unit			::	□B+ □ O-	□ AB-	□ N/A							
:		Partial unitmL mL mtial unitPartial unit			::	□B+ □ O-	□ AB- □ O+	□ N/A	N						
:		Partial unitmL mL			::	□B+ □ O- □ A- □B+	□ AB- □ O+ □ A+ □ AB-	□ N/A □ B- □ AB+	N						
:	☐ ISBT-128 ☐ Codabar	Partial unitmL mL mtial unitPartial unit			:: ::	□B+ □ O-	□ AB- □ O+	□ N/A	N						
:	☐ ISBT-128 ☐ Codabar	Partial unitmL mL mtial unitPartial unit			: : :	□B+ □ O- □ A- □B+	□ AB- □ O+ □ A+ □ AB-	□ N/A □ B- □ AB+	N						
::	☐ ISBT-128 ☐ Codabar	Partial unitmL mL mtial unitPartial unit		Label	:::	□B+ □ O- □ A- □B+	□ AB- □ O+ □ A+ □ AB-	□ N/A □ B- □ AB+	N						
	☐ ISBT-128 ☐ Codabar	Partial unitmL mL mtial unitPartial unit		Label	::::	□B+ □ O- □ A- □B+	□ AB- □ O+ □ A+ □ AB-	□ N/A □ B- □ AB+	N						
Label	☐ ISBT-128 ☐ Codabar	Partial unitmL mL mtial unitPartial unit		Label	:	□B+ □ O- □ A- □B+	□ AB- □ O+ □ A+ □ AB-	□ N/A □ B- □ AB+	N N						
	☐ ISBT-128 ☐ Codabar	Partial unitmL mL mtial unitPartial unit		Label	::::	□B+ □ O- □ A- □B+	□ AB- □ O+ □ A+ □ AB-	□ N/A □ B- □ AB+	N						
Label	☐ ISBT-128 ☐ Codabar	Partial unitmL mL mtial unitPartial unit		Label	: : :	□B+ □ O- □ A- □B+	□ AB- □ O+ □ A+ □ AB-	□ N/A □ B- □ AB+	N						